Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective

Background: Atrial fibrillation (AF) affects approximately 350,000 Canadians and has an estimated annual economic burden exceeding $800 million dollars. Anti-arrhythmic drug (AAD) therapy and catheter ablation (CA) are the two common treatments for paroxysmal AF. However, the upfront costs of CA are...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaykin, Yaariv, Mallow, Peter J., Rizzo, John A., Verma, Atul, Chun, Lauren, Olesovsky, Shelby, Reynolds, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2016
Materias:
Cardiovascular Conditions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471365/
https://www.ncbi.nlm.nih.gov/pubmed/37662659
http://dx.doi.org/10.36469/9837

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471365/
https://www.ncbi.nlm.nih.gov/pubmed/37662659
http://dx.doi.org/10.36469/9837

Ejemplares similares